PER-008-10招募中未知
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NERATINIB (HKI-272) AFTER TRASTUZUMAB IN WOMEN WITH EARLY-STAGE HER-2/NEU OVEREXPRESSED/AMPLIFIED BREAST CANCER
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 120（—）
- 性别
- Female
入选标准
- •Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease.
- •Been treated for early breast cancer with standard of care duration of trastuzumab.
- •Could have been treated neoadjuvantly but have not reached pCR.
排除标准
- •Positive clinical and radiologic assessments for local or regional recurrence of disease at the time of study entry.
- •History of heart disease.
- •QTc interval > 0.45 seconds
- •History of gastrointestinal disease with diarrhea as the major symptom.
研究者
相似试验
进行中（未招募）
1 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITISAtopic dermatitisEUCTR2019-002932-10-LTDermira, a wholly owned subsidiary of Eli Lilly and Company400
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THEPREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERALNEUROPATHY SYMPTOMS WITH PREGABALIN IN SUBJECTS WITH ADVANCED COLORECTAL CANCER - naCHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMSMedDRA version: 8.1Level: LLTClassification code 10029331Term: Neuropathy peripheralEUCTR2006-002917-11-DEPfizer Pharma GmbH200
进行中（未招募）
1 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITISMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2019-002932-10-EEDermira, a wholly owned subsidiary of Eli Lilly and Company400
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMS IN SUBJECTS WITH ADVANCED COLORECTAL CANCER - NDEUCTR2006-002917-11-ITPFIZER200
进行中（未招募）
1 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITISAtopic dermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2019-002932-10-ESDermira, Inc.424